Skip to Main Content

Paper Details

Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
Crit Rev Oncol Hematol
1
2023
Author NameAffiliation
Sara M TolaneyDana-Farber Cancer Institute, USA Harvard Medical School
  • 1 - 1

Datasets

Release 1.2